Related references
Note: Only part of the references are listed.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng et al.
LEUKEMIA (2017)
Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods
Christopher Jackson et al.
MEDICAL DECISION MAKING (2017)
Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma
Ronald S. Go et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
Robert Z. Orlowski et al.
CANCER (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J. Shah et al.
BLOOD (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914
Eva M. Huber et al.
STRUCTURE (2015)
The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence
Gisela Hostenkamp et al.
SOCIAL SCIENCE & MEDICINE (2015)
Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma
Irina Proskorovsky et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Peter A. Ubel et al.
HEALTH AFFAIRS (2012)
Management of treatment-emergent peripheral neuropathy in multiple myeloma
P. G. Richardson et al.
LEUKEMIA (2012)
Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
Bruce E. Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
What does the value of modern medicine say about the $50,000 per Quality-Adjusted Life-Year decision rule?
R. Scott Braithwaite et al.
MEDICAL CARE (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
D Chauhan et al.
BLOOD (2004)
A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study
M van Agthoven et al.
EUROPEAN JOURNAL OF CANCER (2004)
Share Paper
